-
Gastroenterology: mTORC1/2 gathers on the Arp2/3 complex to promote the progression of → catheterized bio→ and early pancreatic cancer transformation
Time of Update: 2021-01-14
mTORC2 activates the Arp2/3 complex via the Akt/Rac1 signal axis in consistent with the above results, ablation of the Arp2/3 complex gene can block Kras-driven ADMs in the body.
-
Lancet sub-journal: Karelli pearl single anti-scale non-scale NSCLC maximum total lifetime
Time of Update: 2021-01-14
For patients with advanced non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALC mutations, immunotherapy in combination with chemotherapy is the most common and effective treatment.
-
Cell: Uncover the "bad link" between obesity and cancer! Excess fat helps cancer cells "suppress" immune cells and accelerate tumor growth
Time of Update: 2021-01-14
Compared to tumors in obese mice (below), tumors in non-obese mice (above) contained more CD8 plus T cells (source: Cell) and they found that an increase in expression of PHD3, a protein shown in normal cells to inhibit excessive fat metabolism, could largely reverse the negative effects of a high-fat diet on tumor immune cell function and may have the potential to be a target for future treatments for many cancers.
-
Wu Zhoupeng: Prevention and treatment of VTE recurrence of venous thromboembolism in patients with malignant tumors
Time of Update: 2021-01-14
Coagulation: APTT 39.2 s, FIB 3.36 g/L, TT 16.9 s, D-Diajuly (ELISA) 2089 μg/L Treatment: Transvascular Surgery, 7 days in hospital, regular anticoagulant, left upper limb pain and swelling significantly reduced, discharged with the drug Inoparin (6000 IU, Bid).
-
Lancet oncol:S-1 complementary therapy combined endocrine therapy is used for the efficacy and safety of ER-Her2-primary invasive breast cancer
Time of Update: 2021-01-14
155 patients (16%) in the single endocrine therapy group and 101 (11%) in the joint group received non-invasive disease survival events (risk ratio of 0.63,95% CI 0.49-0.81, p=0.0003).
, the study suggests that S-1 combined endocrine therapy could be a potential treatment option for patients with high-risk ER-positive, HER2-negative primary breast cancer.
-
Lancet Oncol: Adenovirus transfected interferon α-2b in the bladder can effectively treat BCG non-reactive non-muscle-immersive bladder cancer
Time of Update: 2021-01-14
6 patients were excluded from BCG's non-reactive non-muscular leaching bladder cancer definition; 55 (53.4%) of the 103 in-place cancer patients (with or without high-level Stage Ta or T1 tumors) received complete remission within 3 months of the application of dose 1 treatment, of which 25 (45.5%) had a remission period that lasted until the 12th month.
-
Lancet Oncol: The treatment of advanced kidney cancer in the first stage of treatment of Pym monoantigen is better than that of single-use schoinib (Keynote-426)
Time of Update: 2021-01-14
The first interim analysis of the Keynote-426 study showed that the efficacy of Pym monoantigeno-axial therapy for advanced kidney cancer was better than that of single-use schoinib.
, by extending follow-up, the results of the Keynote-426 trial showed that Pym monoantigenic assitinib still had better clinical efficacy than Schoinini.
-
J Exp Med: The relationship between lipid metabolism and tumor development
Time of Update: 2021-01-14
The paper summarizes the research progress of tumor cell lipid metabolism regulation and introduces the new methods of tumor treatment which have been clinically used to interfere with lipid metabolism, and discusses and analyzes the future development trend of the field based on the existing research results.
-
Opioids may be a potential cause of an increased incidence of pancreatic cancer
Time of Update: 2021-01-14
In 1999 and 2016, data on pancreatic cancer morbidity and opioid mortality in each state explained the development of pre-cancer lesions by delaying risk factors by four years.
-
Merca East entered TCE to develop a new cancer immunotherapy
Time of Update: 2021-01-12
Recently, Mercator struck a potentially $1 billion strategic partnership with San Diego-based Janux Therapeutics to develop next-generation T-cell joint (TCE) immunotherapy for cancer treatments.
first generation of TCE triggers a systemic immune response that attacks healthy cells in addition to tumors, potentially life-threatening toxicity, according to Janux's website.
-
What will be the impact of the hierarchical management of cancer drugs?
Time of Update: 2021-01-12
Ma Jun told reporters that in recent years, under the great attention of China's health administration departments, a number of relevant regulations and technical specifications have been issued, and gradually improve and strengthen the selection, procurement, storage, prescription, deployment, clinical application and drug evaluation of the entire process of management.
-
Comfort can be initiated according to the oncology immunotherapy patient relief project
Time of Update: 2021-01-12
Recently, the Beijing Kang League Charitable Foundation, together with Xinda Bio, launched the "Shuxin-Oncology Immunotherapy Patient Relief Project", which was launched on January 1, 2021 and is scheduled to be carried out simultaneously in project pharmacies in 190 cities across the country.
-
NK cell therapy shows early efficacy and safety
Time of Update: 2021-01-06
News Events U.S. biotech company Fate announced the results of its induced erythnic stem cell (iPSC) transformation NK cell therapy FT516 at its on-the-go 2020 annual meeting.
-
Johnson and Johnson and Xencor reach CD28 dual anti-development joint...
Time of Update: 2021-01-06
Xencor will receive $50 million in advance payments and development, regulatory, sales milestone payments, and double-digit sales share based on net sales.
addition, we have developed two companies' anti-prostate cancer portfolio therapies, leveraging Xencor's extensive clinical product line and Johnson and Johnson's leading portfolio of prostate cancer treatments.
-
Fuhong Hanxuan "Adamu single resistance" was approved for listing
Time of Update: 2021-01-06
At present, the domestic Adamo single anti-biosynthic drug research and development is very hot, in addition to Baiotai, Haizheng, Fuhong Hanyu and Xinda, Junshi biological, Zhengtianqing biosychic drugs are also on the market review and approval.
-
SSO Bio announced the completion of nearly RMB300 million round D financing
Time of Update: 2021-01-06
, in December 2019 announced that it had obtained global rights to the "first-in-class" anti-tumor drug from Sunes pharmaceuticals in the United States.
-
Baiji Shenzhou / Anjin cooperation "injection with perintomo double resistance" was approved for listing
Time of Update: 2021-01-06
On December 7, NMPA issued an approval for the domestic market of Amgen's "Injection Perintomo Double Resistance" for the treatment of adult patients with R/R pre-B-cell acute lymphoblastic leukemia (ALL).
-
Glutamine has a smaller molecular weight but is more powerful!
Time of Update: 2021-01-06
4. Science: Glutamine blocking drugs to enhance anti-tumor response are expected to be used in CAR-T cell therapy doi:10.1126/science.aav2588 In a new study, researchers at Johns Hopkins University in the United States have developed a compound that blocks glutamine metabolism to slow tumor growth, alter tumor microenvironment, and promote the production of persistent highly active anti-tumor T cells.
-
Corning Jerry Double Anti-KN026 Joint KN046 Key Clinical Study Completes First...
Time of Update: 2021-01-06
KN026 and KN046 combination therapies achieved initial excellent efficacy and tolerance in an open, multi-center clinical trial for patients with advanced HER2 expression solid tumors who failed standard treatments, and 14 herrings with evaluatable efficacy Among 2 positive patients, objective remission rate (ORR) reached 64.3% and disease control rate (DCR) reached 92.9%, detailed data were recently published at the Annual Meeting of the Society for Cancer Immunotherapy (SITC 2020).
-
The first domestic PARP inhibitor is about to be approved! The anaesthetic market is welcoming 1.1...
Time of Update: 2021-01-06
Hengrui Class 1 new drug "Fluopali Capsules" will soon be approved drug intelligence data show that Hengrui Pharmaceutical Class 1 new drug "Fluorine Paley Capsules" market application to enter the administrative approval stage, is expected to be approved in recent days, the drug is the first domestic enterprises independently developed PARP inhibitors, used to treat patients with BRCA1/2 pathogenic or suspected pathogenic mutations after second-line and above chemotherapy.
